Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Fostering Innovation in Symptom Management among Hemodialysis Patients: Paths Forward for Insomnia, Muscle Cramps, and Fatigue.

Flythe JE, Hilliard T, Lumby E, Castillo G, Orazi J, Abdel-Rahman EM, Pai AB, Rivara MB, St Peter WL, Weisbord SD, Wilkie CM, Mehrotra R; Kidney Health Initiative Prioritizing Symptoms of ESRD Patients for Developing Therapeutic Interventions Stakeholder Meeting Participants.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):150-160. doi: 10.2215/CJN.07670618. Epub 2018 Nov 5.

PMID:
30397026
2.

Drug Therapy Problem Severity Following Hospitalization and Association With 30-Day Clinical Outcomes.

Westberg SM, Yarbrough A, Weinhandl ED, Adam TJ, Brummel AR, Reidt SL, Sick BT, St Peter WL.

Ann Pharmacother. 2018 Dec;52(12):1195-1203. doi: 10.1177/1060028018781919. Epub 2018 Jun 11.

PMID:
29888615
3.

Enhancing guideline-based asthma care processes through a multi-state, multi-center quality improvement program.

Sirikan R, Heins Nesvold J, Pinar KM, St Peter WL, Julian W, Jon C S, Angeline M C.

J Asthma. 2019 Apr;56(4):440-450. doi: 10.1080/02770903.2018.1463378. Epub 2018 May 11.

PMID:
29641271
4.

Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study.

Flythe JE, Hilliard T, Castillo G, Ikeler K, Orazi J, Abdel-Rahman E, Pai AB, Rivara MB, St Peter WL, Weisbord SD, Wilkie C, Mehrotra R.

Clin J Am Soc Nephrol. 2018 May 7;13(5):735-745. doi: 10.2215/CJN.10850917. Epub 2018 Mar 20.

5.
6.

Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.

St Peter WL, Wazny LD, Weinhandl ED.

Am J Kidney Dis. 2018 Feb;71(2):246-253. doi: 10.1053/j.ajkd.2017.09.007. Epub 2017 Nov 28.

PMID:
29195858
7.

Patterns of NSAIDs Use and Their Association with Other Analgesic Use in CKD.

Zhan M, St Peter WL, Doerfler RM, Woods CM, Blumenthal JB, Diamantidis CJ, Hsu CY, Lash JP, Lustigova E, Mahone EB, Ojo AO, Slaven A, Strauss L, Taliercio JJ, Winkelmayer WC, Xie D, Fink JC; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1778-1786. doi: 10.2215/CJN.12311216. Epub 2017 Aug 15.

8.

Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations.

Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, Fischer MJ, Navaneethan S, Delafontaine P, Jaar BG, Ojo A, Makos GK, Slaven A, Weir MR, Zhan M, Fink JC; for CRIC Study Investigators.

Clin J Am Soc Nephrol. 2017 Aug 9;12(9). pii: CJN.12991216. doi: 10.2215/CJN.12991216. Print 2017 Sep 7.

9.

Erratum to: A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

St Peter WL, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ.

Drugs. 2017 Sep;77(14):1611. doi: 10.1007/s40265-017-0798-x. No abstract available.

PMID:
28786038
10.

A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

St. Peter WL, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ.

Drugs. 2017 Jul;77(11):1155-1186. doi: 10.1007/s40265-017-0758-5. Review. Erratum in: Drugs. 2017 Aug 7;:. Peter, Wendy L St [corrected to St. Peter, Wendy L].

PMID:
28584909
11.

Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices.

Shafi T, Sozio SM, Luly J, Bandeen-Roche KJ, St Peter WL, Ephraim PL, McDermott A, Herzog CA, Crews DC, Scialla JJ, Tangri N, Miskulin DC, Michels WM, Jaar BG, Zager PG, Meyer KB, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

Medicine (Baltimore). 2017 Feb;96(5):e5924. doi: 10.1097/MD.0000000000005924.

12.

Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study.

St Peter WL, Yusuf AA, Do T, Lowe KA, Liu J, Nieman KM, Bradbury BD, Collins AJ.

BMC Nephrol. 2015 Mar 31;16:41. doi: 10.1186/s12882-015-0030-8.

13.

Management of Polypharmacy in Dialysis Patients.

St Peter WL.

Semin Dial. 2015 Jul-Aug;28(4):427-32. doi: 10.1111/sdi.12377. Epub 2015 Apr 9.

PMID:
25864928
14.

Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.

Yusuf AA, Howell BL, Powers CA, St Peter WL.

Am J Kidney Dis. 2014 Nov;64(5):770-80. doi: 10.1053/j.ajkd.2014.04.014. Epub 2014 May 13.

15.

Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D.

Yusuf AA, Weinhandl ED, St Peter WL.

Am J Kidney Dis. 2014 Jul;64(1):95-103. doi: 10.1053/j.ajkd.2013.11.015. Epub 2013 Dec 31.

16.

Predialysis systolic BP variability and outcomes in hemodialysis patients.

Shafi T, Sozio SM, Bandeen-Roche KJ, Ephraim PL, Luly JR, St Peter WL, McDermott A, Scialla JJ, Crews DC, Tangri N, Miskulin DC, Michels WM, Jaar BG, Herzog CA, Zager PG, Meyer KB, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

J Am Soc Nephrol. 2014 Apr;25(4):799-809. doi: 10.1681/ASN.2013060667. Epub 2014 Jan 2.

17.

Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months.

St Peter WL, Sozio SM, Shafi T, Ephraim PL, Luly J, McDermott A, Bandeen-Roche K, Meyer KB, Crews DC, Scialla JJ, Miskulin DC, Tangri N, Jaar BG, Michels WM, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End-Stage Renal Disease Study Investigators.

BMC Nephrol. 2013 Nov 12;14:249. doi: 10.1186/1471-2369-14-249.

18.

The authors reply.

Liu J, Weinhandl ED, Collins AJ, St Peter WL.

Kidney Int. 2013 Nov;84(5):1053. doi: 10.1038/ki.2013.261. No abstract available.

19.

New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management.

St Peter WL, Wazny LD, Patel UD.

Curr Opin Nephrol Hypertens. 2013 Nov;22(6):656-62. doi: 10.1097/MNH.0b013e328365b364. Review.

20.

Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.

Pai AB, Cardone KE, Manley HJ, St Peter WL, Shaffer R, Somers M, Mehrotra R; Dialysis Advisory Group of American Society of Nephrology.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1988-99. doi: 10.2215/CJN.01420213. Epub 2013 Aug 29.

21.

In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'.

St Peter WL, Weinhandl ED, Flessner MF.

Am J Kidney Dis. 2013 Sep;62(3):642-3. doi: 10.1053/j.ajkd.2013.06.009. No abstract available.

PMID:
23972059
22.

Racial differences in clinical use of cinacalcet in a large population of hemodialysis patients.

Newsome BB, Kilpatrick RD, Liu J, Zaun D, Solid CA, Nieman K, St Peter WL.

Am J Nephrol. 2013;38(2):104-14. doi: 10.1159/000353298. Epub 2013 Jul 30.

23.

Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.

Ye X, Qian C, Liu J, St Peter WL.

Pharmacotherapy. 2013 Oct;33(10):1062-70. doi: 10.1002/phar.1317. Epub 2013 Jun 24.

24.

Trends in hip fracture rates in US hemodialysis patients, 1993-2010.

Arneson TJ, Li S, Liu J, Kilpatrick RD, Newsome BB, St Peter WL.

Am J Kidney Dis. 2013 Oct;62(4):747-54. doi: 10.1053/j.ajkd.2013.02.368. Epub 2013 Apr 28.

PMID:
23631997
25.

Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement report.

Weinhandl ED, Arneson TJ, St Peter WL.

Am J Kidney Dis. 2013 Sep;62(3):557-67. doi: 10.1053/j.ajkd.2013.02.360. Epub 2013 Apr 16.

PMID:
23597860
26.

To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.

St Peter WL, Odum LE, Whaley-Connell AT.

Pharmacotherapy. 2013 May;33(5):496-514. doi: 10.1002/phar.1232. Epub 2013 Apr 9. Review.

PMID:
23576066
27.

Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients.

Kilpatrick RD, Newsome BB, Zaun D, Liu J, Solid CA, Nieman K, St Peter WL.

Am J Nephrol. 2013;37(4):389-98. doi: 10.1159/000350213. Epub 2013 Mar 29.

PMID:
23548469
28.

Sitagliptin--another option for managing type 2 diabetes in dialysis patients?

St Peter WL, Weinhandl ED, Flessner MF.

Am J Kidney Dis. 2013 Apr;61(4):532-5. doi: 10.1053/j.ajkd.2013.01.004. No abstract available.

PMID:
23497767
29.

Finding a common language for patient safety in CKD.

Fink JC, Joy MS, St Peter WL, Wahba IM; ASN Chronic Kidney Disease Advisory Group.

Clin J Am Soc Nephrol. 2012 Apr;7(4):689-95. doi: 10.2215/CJN.12781211. Epub 2012 Mar 8. Review.

30.

Sources of drug coverage among Medicare beneficiaries with ESRD.

Howell BL, Powers CA, Weinhandl ED, St Peter WL, Frankenfield DL.

J Am Soc Nephrol. 2012 May;23(5):959-65. doi: 10.1681/ASN.2011070740. Epub 2012 Mar 8.

31.

Medicare Part D: challenges for dialysis patients (part 2 of 2): opportunities to improve patient experiences.

Smith S, Witten B, Paykin C, Weiner S, Chianchiano D, St Peter WL.

Nephrol News Issues. 2011 Dec;25(13):24, 26-9. No abstract available.

PMID:
22308830
32.

Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.

Frankenfield DL, Weinhandl ED, Powers CA, Howell BL, Herzog CA, St Peter WL.

Am J Kidney Dis. 2012 May;59(5):670-81. doi: 10.1053/j.ajkd.2011.10.047. Epub 2011 Dec 28.

PMID:
22206743
33.

Medicare Part D: challenges for dialysis patients. Part 1.

Smith S, Witten B, Paykin C, Weiner S, Chianchiano D, St Peter WL.

Nephrol News Issues. 2011 Nov;25(12):38-40, 42, 44-5.

PMID:
22204167
34.

Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.

Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL.

Kidney Int. 2012 Feb;81(4):341-50. doi: 10.1038/ki.2011.388. Epub 2011 Nov 16. Review.

35.

Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients.

St Peter WL, Farley TM, Carter BL.

Curr Opin Nephrol Hypertens. 2011 Sep;20(5):498-503. doi: 10.1097/MNH.0b013e32834902c8. Review.

PMID:
21709550
36.

Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007.

Li S, Chen YW, Peng Y, Foley RN, St Peter WL.

Am J Kidney Dis. 2011 Apr;57(4):602-11. doi: 10.1053/j.ajkd.2010.10.041. Epub 2010 Dec 24.

PMID:
21186072
37.

Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation.

St Peter WL.

Adv Chronic Kidney Dis. 2010 Sep;17(5):413-9. doi: 10.1053/j.ackd.2010.06.001. Review.

PMID:
20727511
38.

Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.

Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL.

Kidney Int. 2010 Sep;78(6):578-89. doi: 10.1038/ki.2010.167. Epub 2010 Jun 16.

39.

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.

St Peter WL, Fan Q, Weinhandl E, Liu J.

Clin J Am Soc Nephrol. 2009 Dec;4(12):1954-61. doi: 10.2215/CJN.04100609. Epub 2009 Oct 15.

40.

Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.

St Peter WL, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ.

Pharmacotherapy. 2009 Feb;29(2):154-64. doi: 10.1592/phco.29.2.154.

PMID:
19170585
41.

Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.

St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA.

Clin J Am Soc Nephrol. 2009 Feb;4(2):354-60. doi: 10.2215/CJN.05241008. Epub 2009 Jan 7.

42.

Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.

St Peter WL, Liu J, Weinhandl ED, Fan Q.

Hemodial Int. 2008 Oct;12(4):480-91. doi: 10.1111/j.1542-4758.2008.00312.x.

PMID:
19090871
43.

Vitamin D use and mortality in chronic kidney disease: immortal time bias.

St Peter WL, Weinhandl ED, Liu J.

Arch Intern Med. 2008 Nov 24;168(21):2384-5; author reply 2385-6. doi: 10.1001/archinte.168.21.2384. No abstract available.

PMID:
19029507
44.

Potential impact of Medicare Part D in the end-stage renal disease population.

St Peter WL.

Adv Chronic Kidney Dis. 2008 Apr;15(2):140-6. doi: 10.1053/j.ackd.2008.01.014. Review.

PMID:
18334238
46.

Chronic kidney disease and medicare.

St Peter WL.

J Manag Care Pharm. 2007 Dec;13(9 Suppl D):S13-8. Review.

PMID:
18177214
47.

Introduction: chronic kidney disease: a burgeoning health epidemic.

St Peter WL.

J Manag Care Pharm. 2007 Dec;13(9 Suppl D):S2-5. Review.

PMID:
18177212
48.

Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.

Ye X, Gross CR, Schommer J, Cline R, St Peter WL.

Clin Ther. 2007 Dec;29(12):2748-57. doi: 10.1016/j.clinthera.2007.12.022.

PMID:
18201593
49.

Nephrology pharmaceutical care preceptorship: a programmatic and clinical outcomes assessment. 2000.

Matzke GR, St Peter WL, Comstock TJ, Foote EF.

Ann Pharmacother. 2007 Nov;41(11):1892-8. Epub 2007 Oct 16. No abstract available.

PMID:
17940121
50.

Initiation of statins after hospitalization for coronary heart disease.

Ye X, Gross CR, Schommer J, Cline R, Xuan J, St Peter WL.

J Manag Care Pharm. 2007 Jun;13(5):385-96.

Supplemental Content

Loading ...
Support Center